Infectimune®-based Vaccines
Selected deadly infectious diseases
Preclinical/ResearchPipeline - In development
Key Facts
Indication
Selected deadly infectious diseases
Phase
Preclinical/Research
Status
Pipeline - In development
Company
About PDS Biotechnology
PDS Biotech is focused on transforming how the immune system targets and fights disease through its Versamune® T-cell activating platform and its combination with the tumor-targeted IL-12 immunocytokine PDS01ADC. The company has demonstrated promising clinical results in HPV-positive cancers, including a median overall survival of 39.3 months in a Phase 2 head and neck cancer trial. With a growing pipeline in oncology and infectious disease vaccines, PDS Biotech aims to create a new generation of targeted immunotherapies.
View full company profile